|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Level of education and mortality after radical prostatectomy显示文摘估计竞争死亡的风险具有在有早前列腺癌症的人的重要性选择管理的最适当的方法并且避免在处理上或在处理下面。在这研究,我们在这上下文调查了教育的水平的影响。学习样品在教育(学院,大学学位,主人工匠,可比较的职业,或其它)的水平上与完全的数据由 2630 个病人组成了,组织病理学说的肿瘤舞台(限制的机关或囊外),淋巴节点地位(否定或积极),并且前列腺切除术标本格利森分数(< 7 , 7 ,或 8-10 )经历了在 1992 和 2007 之间的激进的前列腺切除术。总的来说,前列腺癌症特定,竞争,并且第二癌症相关的死亡是学习端点。比例的危险为竞争风险建模的考克斯被用来在这些端点上学习变量的联合效果。教育的高水平独立地在激进的前列腺切除术以后与减少的全面死亡被联系(危险比率[HR ] :0.75, 95% 信心间隔[95% CI ] :0.62-0.91, P = 0.0037 ) 。死亡差别对减少的秒可归因癌症死亡(HR:0.59, 95% CI:0.40-0.85, P = 0.0052 ) 并且 noncancer 死亡(HR:0.73, 95% CI:0.55-0.98, P = 0.0345 ) 然而并非到在前列腺的差别癌症特定的死亡(HR:1.16, 95% CI:0.79-1.69, P = 0.4536 在完整的模型) 。在结论,教育的水平可能用作对估计竞争死亡的风险并且与早前列腺癌症为人选择最佳的治疗的年龄, comorbidity,和吸烟地位增补的一个独立预示的参数是激进的前列腺切除术的候选人。 | Michael Froehner Rainer Koch Stefan Propping Dorothea Liebeheim Matthias Hfibler Gustavo B Baretton Oliver W Hakenberg Manfred P Wirth | 2017 | Asian Journal of Andrology2017，19，2： | 1 |
| 2 | Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition显示文摘Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mechanistic target of rapamycin(PI3K-AKT-mTOR)pathway is a driver pathway in PDAC and an important therapeutic target[2].We[3]and others[4–6]have demonstrated that the mTOR kinase is a therapeutic target in PDAC,and rationally designed mTOR inhibitor(mTORi)-based combination therapies are emerging[2]. | Christian Schneeweis Zonera HassanKatja Ascherl Matthias Wirth Stella Koutsouli Felix Orben Lukas Krauß Carolin Schneider Rupert Ollinger Oliver HKrämer Roland Rad Maximilian Reichert Maria SRobles Dieter Saur Günter Schneider | 2022 | Cancer Communications2022，42，4： | 0 |
| 3 | Boosting T cell immunity against cytomegalovirus:a potential strategy combating human aging and age-related diseases显示文摘In a recent publication in Cell,Hasegawa and colleagues reveal that cytotoxic CD4-positive cytotoxic T lymphocytes(CD4+CTLs)eliminate senescent fibroblasts with a surface expression of the immunologically important human leukocyte antigen class Il(HLA-)and the human cytomegalovirus glycoprotein B(HCMV-gB).1 This implies that a virome-immune cell interaction controls the fate of human skin cells that are linked to the aging process and associated diseases. | Matthias Wirth Walburgis Brenner Oliver H.Kramer | 2023 | Signal Transduction and Targeted Therapy2023，8，10： | 0 |
| 4 | Vitamin E treatment for children with chronic hepatitis B:A randomized placebo controlled trial显示文摘AIM:To evaluate the safety and efficacy of vitamin E in children with chronic hepatitis B.METHODS:We randomly assigned patients with chronic hepatitis B,positive for hepatitis B e antigen(HBeAg),to receive either vitamin E or placebo once daily for 6 mo in a 3:1 ratio and double-blind manner.The primary end point was HBeAg seroconversion,defined as the loss of HBeAg,undetectable levels of serum hepatitis B virus DNA,and the appearance of antibodies against HBeAg 12 mo after therapy.RESULTS:At baseline visit,49 patients had normal and 43 had increased serum aminotransferase levels.Twenty-nine patients did not respond to previous treatment with interferon-α or lamivudine.Seventy-six children completed the study;16 were non-compliant(n = 7),lost to follow-up(n = 7),or started another antiviral treatment(n = 3).Intention-to-treat analysis showed HBeAg seroconversion in 16 children(23.2%) treated with vitamin E and two(8.7%) in the placebo group(P = 0.13).Vitamin E was well tolerated.CONCLUSION:There is only a tendency that vitamin E may promote HBeAg seroconversion.Therefore larger studies are needed to clarify the role of antioxidants in the therapy of chronic hepatitis B. | Patrick Gerner Hans-Georg Posselt Andreas Krahl Antje Ballauff Albina Innerhofer Christa Binder Tobias G Wenzl Matthias Zense Ariadne Hector Gerhard Dockter Rüdiger Adam Jenny Neubert Martin Claβen Robert van Gemmern Stefan Wirth | 2008 | World Journal of Gastroenterology2008，14，47： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员